Forte Biosciences (FBRX) Equity Average (2017 - 2020)
Forte Biosciences (FBRX) has disclosed Equity Average for 4 consecutive years, with $22.6 million as the latest value for Q3 2020.
- Quarterly Equity Average rose 881.41% to $22.6 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $22.6 million through Sep 2020, up 881.41% year-over-year, with the annual reading at -$2.8 million for FY2019, 107.83% down from the prior year.
- Equity Average for Q3 2020 was $22.6 million at Forte Biosciences, up from $9.1 million in the prior quarter.
- The five-year high for Equity Average was $84.3 million in Q3 2017, with the low at -$128.7 million in Q1 2017.
- Average Equity Average over 4 years is $14.2 million, with a median of $9.1 million recorded in 2020.
- Peak annual rise in Equity Average hit 881.41% in 2020, while the deepest fall reached 334.69% in 2020.
- Over 4 years, Equity Average stood at $75.6 million in 2017, then tumbled by 68.96% to $23.5 million in 2018, then tumbled by 117.06% to -$4.0 million in 2019, then surged by 664.61% to $22.6 million in 2020.
- According to Business Quant data, Equity Average over the past three periods came in at $22.6 million, $9.1 million, and -$5.8 million for Q3 2020, Q2 2020, and Q1 2020 respectively.